BioNTech
NEWS
It’s likely that more companies and universities will add additional assets as time goes on.
It was a very busy week for clinical trial news. Here’s a look.
Pfizer and BioNTech updated their development program, with plans to launch clinical trials in the U.S. and Europe across multiple sites by the end of April.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 9, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
While the world is working to slow the COVID-19 pandemic by social isolation and quarantine, numerous companies globally are working to develop a vaccine against the virus.
The two companies will focus on BioNTech’s BNT162, an mRNA-based vaccine candidate.
The companies intend to push the vaccine candidate into human trials by April of this year, subject to regulatory approval.
“This acquisition fits with our strategy to expand our capabilities and build our presence in the U.S. and further strengthens our immunotherapy pipeline,” said Ugur Sahin, co-founder and chief executive officer of BioNTech.
JOBS
IN THE PRESS